Alcon vs Glaukos: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Alcon AG (ALC.SW)

Q3 20266 Aug – 2 Sep 2026

▲2▼1

Alcon Beats and Raises, but Faces New US Drug Pricing Deals

Strong Q2 results and raised guidance Alcon's second-quarter sales rose 8% to $2.8 billion, and the company raised its full-year outlook for core operating margin and earnings per share growth. This tells investors the core business is performing better than expected, which supports a higher share price.
This is the most direct positive driver of Alcon's value this period.
RxSight collaboration expands premium lens offerings Alcon and RxSight are teaming up on adjustable intraocular lenses, combining RxSight's technology with Alcon's global sales reach. This opens a new premium product line for Alcon and validates its strategy in advanced eye surgery, a positive for future growth.
It shows a new growth avenue that can lift Alcon's long-term sales and pricing power.
Alcon joins US most-favored-nation drug pricing deals Alcon agreed to lower prices on outpatient drugs for state Medicaid programs to match international levels, in exchange for relief from import tariffs. This could pressure Alcon's US pricing and revenue, though the tariff relief and voluntary state participation soften the blow.
It is a new regulatory headwind that directly affects Alcon's pricing and profitability.

August 20266 Aug – 2 Sep 2026

▲2▼1

Alcon Beats and Raises, but Faces New US Drug Pricing Deals

Strong Q2 results and raised guidance Alcon's second-quarter sales rose 8% to $2.8 billion, and the company raised its full-year outlook for core operating margin and earnings per share growth. This tells investors the core business is performing better than expected, which supports a higher share price.
This is the most direct positive driver of Alcon's value this period.
RxSight collaboration expands premium lens offerings Alcon and RxSight are teaming up on adjustable intraocular lenses, combining RxSight's technology with Alcon's global sales reach. This opens a new premium product line for Alcon and validates its strategy in advanced eye surgery, a positive for future growth.
It shows a new growth avenue that can lift Alcon's long-term sales and pricing power.
Alcon joins US most-favored-nation drug pricing deals Alcon agreed to lower prices on outpatient drugs for state Medicaid programs to match international levels, in exchange for relief from import tariffs. This could pressure Alcon's US pricing and revenue, though the tariff relief and voluntary state participation soften the blow.
It is a new regulatory headwind that directly affects Alcon's pricing and profitability.

Latest6 Aug – 2 Sep 2026

▲2▼1

Alcon Beats and Raises, but Faces New US Drug Pricing Deals

Strong Q2 results and raised guidance Alcon's second-quarter sales rose 8% to $2.8 billion, and the company raised its full-year outlook for core operating margin and earnings per share growth. This tells investors the core business is performing better than expected, which supports a higher share price.
This is the most direct positive driver of Alcon's value this period.
RxSight collaboration expands premium lens offerings Alcon and RxSight are teaming up on adjustable intraocular lenses, combining RxSight's technology with Alcon's global sales reach. This opens a new premium product line for Alcon and validates its strategy in advanced eye surgery, a positive for future growth.
It shows a new growth avenue that can lift Alcon's long-term sales and pricing power.
Alcon joins US most-favored-nation drug pricing deals Alcon agreed to lower prices on outpatient drugs for state Medicaid programs to match international levels, in exchange for relief from import tariffs. This could pressure Alcon's US pricing and revenue, though the tariff relief and voluntary state participation soften the blow.
It is a new regulatory headwind that directly affects Alcon's pricing and profitability.

Glaukos Corp (GKOS)

Q3 202630 Jul – 9 Oct 2026

▲3

Glaukos Surges on iDose TR and Epioxa Ramp, Raises Guidance

iDose TR and Epioxa drive record revenue and raised guidance Glaukos reported Q2 revenue of $185.6 million, up 50% year over year, with U.S. glaucoma revenue up 64% to $118.5 million and iDose TR sales reaching about $74 million. Management raised 2026 revenue guidance to $680–$700 million, up from $620–$635 million, citing strong adoption of iDose TR and the Epioxa launch. This boosts investor confidence in the growth trajectory.
This is the core fundamental driver behind the stock's surge and guidance raise.
Epioxa shows durable three-year efficacy in keratoconus Glaukos reported positive three-year Phase 3 extension data for Epioxa, showing lasting visual gains and no serious safety issues in keratoconus patients after a single treatment. This supports the corneal health franchise as a second growth pillar alongside glaucoma, potentially expanding the market opportunity and reinforcing long-term revenue prospects.
New clinical data validates a key growth product and supports the investment thesis.
iDose TR plus cataract surgery cuts eye pressure significantly A Phase 4 trial showed iDose TR combined with cataract surgery reduced intraocular pressure by 11.1 mmHg at three months, beating cataract surgery alone by 3.6 mmHg, with a favorable safety profile. This expands the potential use of iDose TR to a large cataract surgery population, opening a new avenue for adoption and revenue growth.
New clinical evidence broadens the addressable market for the flagship product.
Retinal pipeline expansion via RevOpsis license, but stock dipped Glaukos licensed RO-104, a tri-specific biologic for retinal diseases, and gained exclusive rights to the RevMod platform to develop up to four more candidates. While this expands the long-term pipeline, the stock fell 6.3% on the news, possibly due to undisclosed financial terms or investor preference for nearer-term catalysts.
New strategic move with mixed market reaction, relevant to future growth but not immediate revenue.

September 202630 Jul – 9 Oct 2026

▲3

Glaukos Surges on iDose TR and Epioxa Ramp, Raises Guidance

iDose TR and Epioxa drive record revenue and raised guidance Glaukos reported Q2 revenue of $185.6 million, up 50% year over year, with U.S. glaucoma revenue up 64% to $118.5 million and iDose TR sales reaching about $74 million. Management raised 2026 revenue guidance to $680–$700 million, up from $620–$635 million, citing strong adoption of iDose TR and the Epioxa launch. This boosts investor confidence in the growth trajectory.
This is the core fundamental driver behind the stock's surge and guidance raise.
Epioxa shows durable three-year efficacy in keratoconus Glaukos reported positive three-year Phase 3 extension data for Epioxa, showing lasting visual gains and no serious safety issues in keratoconus patients after a single treatment. This supports the corneal health franchise as a second growth pillar alongside glaucoma, potentially expanding the market opportunity and reinforcing long-term revenue prospects.
New clinical data validates a key growth product and supports the investment thesis.
iDose TR plus cataract surgery cuts eye pressure significantly A Phase 4 trial showed iDose TR combined with cataract surgery reduced intraocular pressure by 11.1 mmHg at three months, beating cataract surgery alone by 3.6 mmHg, with a favorable safety profile. This expands the potential use of iDose TR to a large cataract surgery population, opening a new avenue for adoption and revenue growth.
New clinical evidence broadens the addressable market for the flagship product.
Retinal pipeline expansion via RevOpsis license, but stock dipped Glaukos licensed RO-104, a tri-specific biologic for retinal diseases, and gained exclusive rights to the RevMod platform to develop up to four more candidates. While this expands the long-term pipeline, the stock fell 6.3% on the news, possibly due to undisclosed financial terms or investor preference for nearer-term catalysts.
New strategic move with mixed market reaction, relevant to future growth but not immediate revenue.

Latest30 Jul – 9 Oct 2026

▲3

Glaukos Surges on iDose TR and Epioxa Ramp, Raises Guidance

iDose TR and Epioxa drive record revenue and raised guidance Glaukos reported Q2 revenue of $185.6 million, up 50% year over year, with U.S. glaucoma revenue up 64% to $118.5 million and iDose TR sales reaching about $74 million. Management raised 2026 revenue guidance to $680–$700 million, up from $620–$635 million, citing strong adoption of iDose TR and the Epioxa launch. This boosts investor confidence in the growth trajectory.
This is the core fundamental driver behind the stock's surge and guidance raise.
Epioxa shows durable three-year efficacy in keratoconus Glaukos reported positive three-year Phase 3 extension data for Epioxa, showing lasting visual gains and no serious safety issues in keratoconus patients after a single treatment. This supports the corneal health franchise as a second growth pillar alongside glaucoma, potentially expanding the market opportunity and reinforcing long-term revenue prospects.
New clinical data validates a key growth product and supports the investment thesis.
iDose TR plus cataract surgery cuts eye pressure significantly A Phase 4 trial showed iDose TR combined with cataract surgery reduced intraocular pressure by 11.1 mmHg at three months, beating cataract surgery alone by 3.6 mmHg, with a favorable safety profile. This expands the potential use of iDose TR to a large cataract surgery population, opening a new avenue for adoption and revenue growth.
New clinical evidence broadens the addressable market for the flagship product.
Retinal pipeline expansion via RevOpsis license, but stock dipped Glaukos licensed RO-104, a tri-specific biologic for retinal diseases, and gained exclusive rights to the RevMod platform to develop up to four more candidates. While this expands the long-term pipeline, the stock fell 6.3% on the news, possibly due to undisclosed financial terms or investor preference for nearer-term catalysts.
New strategic move with mixed market reaction, relevant to future growth but not immediate revenue.